WST · 10-Q · 2026Q3

WEST PHARMACEUTICAL SERVICES INC

Filed 2026-10-29 · Healthcare · View original filing on EDGAR

Everything WST's SEC filings said, ranked

Ranked Events

• Operating Profit and MarginsImportance 69 · Surprise 64
  Consolidated GAAP operating profit increased 59.5% to $267.4 million in the third quarter of 2026 and 45.6% to $623.6 million in the first nine months; reported operating margins were 30.6% and 24.1%, respectively.…
• Revenue Performance and MixImportance 60 · Surprise 40
  For the three months ended September 30, 2026, consolidated organic net sales grew 11.9% year over year, with volume and mix contributing $58.3 million and price increases contributing $33.6 million. Proprietary…
• Acquisition / Partnership / DivestitureImportance 59 · Surprise 60
  On July 1, 2026, West sold its SmartDose® 3.5mL On-Body Delivery System product line to AbbVie, reducing third-quarter sales by $18.0 million compared with the prior-year quarter. The sale of the assets generated a…
• Operating Cash Flow TrendsImportance 54 · Surprise 40
  Net cash provided by operating activities decreased $100.3 million, from $503.7 million to $403.4 million, for the nine months ended September 30, 2026. The decline was primarily driven by increased customer accounts…
• Liquidity and Debt PositionImportance 51 · Surprise 38
  At September 30, 2026, West held $464.1 million in cash and cash equivalents and had total debt of $202.9 million, essentially unchanged from $202.8 million at December 31, 2025. The company had no borrowings under its…
• Gross Margin DriversImportance 48 · Surprise 40
  Consolidated gross profit for the third quarter of 2026 increased $53.1 million, or 18.0%, to $347.4 million, and gross margin expanded 3.1 percentage points to 39.7%; nine-month gross profit rose $172.9 million, or…
• Interest Rate EnvironmentImportance 45 · Surprise 64
  For the nine months ended September 30, 2026, net interest expense increased $7.6 million year over year, from $0.7 million to $8.3 million. The filing attributes the increase primarily to lower capitalized interest,…
• Operating Expense TrendsImportance 41 · Surprise 22
  Consolidated SG&A increased 9.9% to $112.9 million in the third quarter of 2026 and 15.1% to $330.0 million in the first nine months, while SG&A as a share of sales was 12.9% and 12.7%, respectively. Nine-month…
• Income Tax Rate ChangesImportance 39 · Surprise 50
  The effective tax rate for the three months ended September 30, 2026 was 21.7%, compared with 19.8% in the prior-year quarter, on income tax expense of $58.0 million versus $34.0 million. The quarterly rate increase…
• Share Repurchase ProgramImportance 33 · Surprise 42
  West repurchased 2,424,121 shares of common stock during the nine months ended September 30, 2026, for $685.3 million, at an average price of $282.68 per share. The company identified share repurchases as a primary…

Revenue by Product (in millions)